Development of molecular Imaging for a new amyloidosis (AD,FAP)

新型淀粉样变性（AD、FAP）分子影像学的发展

• 批准号: 23591781
• 负责人: TOMIYOSHI Katsumi
• 金额: $ 3.24万
• 依托单位: Kumamoto University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011 至 2013
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23591781/
• 关键词: PET; アルツハイマー病; SPECT; 標識合成; アミロイドーシス; 18F-EFSB; 125I-EISB; PET検査試薬; 11C-PIB; PIB; アルツハイマー; ピッツバーグ大学

[11C]PIB was synthesized and evaluated Quality control for Clinical use. By applying purification system,Radiochemical yield was 62.7% and radiochemical purity was 95% and more. On the other hand, EMSB (1-(2-mestyl-ethoxy)-2,5bis (phenylstyryl)benzene) is newly synthesized and (1-(125I-ethoxy)-2,5-bis (phenylstyryl) benzene) [125I]-EISB was obtained. The radiochemical yield and the radiochemical purity were 80-90% and 98.4% respectively. We injected [125I]-EISB to Alzheimer model mouse and analyzed its bio-distribution (%dose/g) of [125I]-EISB in the amyloid tissues. In the animal experiments showed that the bio-distribution (%dose/g) of [125I]-EISB gave a similar to the uptake as well as fluorescent agents MSB and PIB which have done in our institute. [125I]-EISB was a promising new radio-compound for the detection of the amyloid protein and make it possible to apply it to clinical use.

合成了[11 C]PIB，并评价了临床使用的质量控制。应用纯化系统，放化收率达62.7%，放化纯度达95%以上。另一方面，本文合成了新的化合物EMSB（1-（2-甲基乙氧基）-2，5-双（苯基苯乙烯基）苯），并合成了（1-（125 I-乙氧基）-2，5-双（苯基苯乙烯基）苯）[125 I]-EISB。放化产率为80-90%，放化纯度为98.4%。我们将[125 I]-EISB注射到阿尔茨海默病模型小鼠中，并分析其在淀粉样组织中的生物分布（%剂量/g）。在动物实验中，[125 I]-EISB的生物分布（%剂量/g）与我们所做的荧光剂MSB和PIB的摄取相似。[125 I]-EISB是一种很有前途的新型放射性化合物，可用于淀粉样蛋白的检测，并使其应用于临床成为可能。